Intercept Pharmaceuticals (ICPT) Soars On 2014 Anticipated Milestones Expectations

Shares of Intercept Pharmaceuticals, Inc. (ICPT) are trading on different levels after the company provided a clinical update on obeticholic acid, a novel bile acid analog and first-in-class agonist of the farnesoid X receptor, currently being developed in a Phase 3 trial f

Online PR News – 12-January-2014 – Las Vegas, NV – Shares of Intercept Pharmaceuticals, Inc. (ICPT) are trading on different levels after the company provided a clinical update on obeticholic acid, a novel bile acid analog and first-in-class agonist of the farnesoid X receptor, currently being developed in a Phase 3 trial for primary biliary cirrhosis, as well as Phase 2 trials for several chronic indications including nonalcoholic steatohepatitis, portal hypertension and bile acid diarrhea, together with projected 2014 anticipated milestones. ICPT's price target was raised: - from $270.00 to $375.00 by brokerage firm BMO Capital - from $94.00 to $360.00 by brokerage firm Oppenheimer - from $60.00 to $400.00 by brokerage firm Citigroup - from $81.00 to $872.00 by brokerage firm BofA/Merrill ICPT is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat orphan and more prevalent liver diseases utilizing its expertise in bile acid chemistry. ICPT's lead product candidate, obeticholic acid, has received orphan drug designation in both the United States and Europe for the treatment of primary biliary cirrhosis. ICPT owns worldwide rights to obeticholic acid outside of Japan and China, where it has out-licensed the product candidate to Dainippon Sumitomo Pharma. More about Intercept Pharmaceuticals, Inc. (ICPT) at www.interceptpharma.com.

Social networking is based on a certain structure that allow people to both express their individuality and meet people with similar interests. This structure includes having profiles, friends, blog posts, widgets, and usually something unique to that particular social networking website. Crown Equity Holdings Inc. (CRWE) is looking to deliver value for its stockholders in both the near and long term, targeting the multi-billion dollar social networking service market. CRWE is currently developing a social networking service and phone app, CRWE Network (CRWE-PR.com), that is designed to target all the communities in every state of the United States, with its geographic focus starting in Southern California and Las Vegas Nevada. CRWE€˜s business plan is based on selling advertising to local businesses. Its goal is to facilitate exchanges of goods and services in a manner similar to Craigslist, a classified advertisements website with sections devoted to jobs, housing, personals, for sale, items wanted, services, community, gigs, résumés, and discussion forums. CRWE offers advertising branding and marketing services as a worldwide online multi-media publisher. More about Crown Equity Holdings Inc. (CRWE) at www.crownequityholdings.com.

Read Full Disclaimer at www.pennyomega.com/disclaimer

Bookmarkse-mailGoogledel.icio.usStumbleUponSlashdotFurlDiggTechnoratiYahooMyWebBlinkListSpurlRawSugarWists
 
 
Contact Information
Jhonny
Bestotc
5440 W. Sahara Ave., Suite 205
Las Vegas NV, 89146

702 448 1543